Thiocolchicoside is a most common used muscle relaxant in the case of treating acute painful muscle spasms. It has a selective affinity for the inhibitory gamma-amino butyric acid and glycinergic receptors, although, the proper pathway of the muscle relaxation is unknown till the date. This drug should be strictly prohibited in the patients causing seizures. The recent studies done by the European medicines agency says that it causes aneuploidy which leads to use of the drug for limited time period which was earlier considered safe. Aneuploidy is a common chromosome disorder occurring in the humans, which leads to genetic cause of miscarriage, congenital birth defects and reduced fertility in men. During pregnancy, in breastfeeding and in children below 16 years, Thiocolchicoside is contraindicated.

Thiocolchicoside and Famotidine are both have known to be used in joint pain or in the treatment of rheumatoid arthritis, etc. But the problem arises in the bioavailability and absorption of these drugs in the body. The current study deals with the design and evaluation of crystal co-agglomerates prepared with the use of various concentration of polymers like HPMC K15M and PVA. The aim of the study was to improvise the flow property, wettability, and dissolution property of the drug and to enhance its absorption in the body which will give better therapeutic response. The prepared co-agglomerates were evaluated for the parameters and it was found that the F4 bath was optimum because better flow ability, maximum drug content and increased dissolution property. SEM study shows the clear cylindrical crystals formed and the stability study shows that the prepared co-agglomerates were stable for the period of time without any significant change in the preparation. It was concluded that the preparation of crystal co-agglomerates was a successful approach in improving the various properties which can reduce the chances of metabolism of drug and will give better therapeutic response and stability of the drug.

The aims of review are the latest research development of the lipid based carriers according to the recent relevant literatures. Each preparation of the lipid based Nanoparticles (SLMs) have advantages and disadvantages. The SLMs is an excellent drug delivery system and has broad prospects in the pharmaceutical field. This review discusses the advantages, therapeutic application of SLMs, various techniques of preparation, and different routes of administration, material use and characterization of solid lipid Nanoparticles.

A rapid, sensitive and accurate method for Estimation of Anti- Histamine in Tablet Dosage Form by RP-HPLC. Mobile phase was Methanol: 0.1% Ortho phosphoric acid (80:20% v/v). Flow rate was 0.9 ml/min. The detection Wavelength was 227 nm. The injection volume was 20-µl. The proposed method was validated for selectivity, precision, linearity, and accuracy. All validation parameters were within the acceptable range. Linearity studies for Levamisole was performed (10-60µg/ml). The %RSD for accuracy found to be less than2%. Assay was found to be 99.17 to 101.65 respectively The range of 10-60µg /ml was selected for the linearity of a standard Levamisole. The 80%, 100% and 120% levels of recovery study were selected to perform the recovery study. Linearity studies for Levamisole was performed on (10-60µg /ml).

Literature survey reveals that few spectrophotometric, high performance liquid chromatographic (HPLC) and High Performance Thin Layer Chromatographic (HPTLC) methods were reported for the estimation of Flavoxate HCl in single and in combined dosage forms. But there is no any stability indicating UV spectroscopic study is reported for Flavoxate in single dosage form. So the present study was aimed to development of simple, accurate, rapid and economical UV-spectrophotometric stability indicating assay method were established for the determination of Flavoxate HCl in bulk and tablet formulation. The solvent was selected for stock solution preparation is water and required concentrations were prepared by using the same solvent. The λmax for detection of Flavoxate HCl is 211nm. In this method Flavoxate followed linearity in the concentrations of 1, 3, 5, 7, 9µg/ml with regression coefficient (r2) 0.999. The percent drug content was found to be 98.81±0.39 for FLV in tablet formulation. Recovery study results of FLV ranges from 99.11 to 100.49%. The method was found to be accurate and precise, as indicate by recovery studies as recoveries were close to 100% and %RSD is less than 2. Inter-day and intraday variation was found to be 0.75 and 0.45%, respectively. The LOD and LOQ values were found to be 0.719µg/ml and 2.186µg/ml, respectively. The stability study of Flavoxate was investigated when the drug was subjected to hydrolytic, peroxide, heat and photolytic (UV and sunlight) degradation. The results express that the Flavoxate is under thermal and photolytic (sunlight and UV light) conditions are more stable. In acidic, basic and hydrogen peroxide conditions Flavoxate is degraded in higher amount.